Superluminal Medicines
United States · Biotech · AI
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
Find drug candidates for hard-to-target receptors
Superluminal's Hyperloop platform brings together GPCR structural models, AI-driven molecule design, large-scale screening, ADMET prediction and experimental validation. It is built to help drug-discovery teams identify and optimize small molecules against receptors whose changing structures make them difficult targets for conventional discovery approaches.
The company is advancing its own programs in endocrine and cardiometabolic disease, including a lead program for rare genetic forms of obesity and hypothalamic obesity, while also working with pharmaceutical partners. Its platform therefore supports both internal pipeline development and collaborations; the medicines remain in development rather than available treatments.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | $60M | BVF Partners, L.P. — LeadCatalio Capital Management — ParticipantCooley — ParticipantDeep Track Capital — ParticipantEli Lilly and Company — ParticipantGaingels — ParticipantInsight Partners — ParticipantNVIDIA — ParticipantPerceptive Advisors — ParticipantRA Capital Management — Participant |